In the third session from the Platelet Reactivity Testing Round Table, the panel discuss treatment options for high-risk PCI patients.
Among the many fascinating points discussed in this session are a number of key issues including (time of discussions within the video are listed in parenthesis):
1:10 – Evidence regarding antiplatelet drug response
3:45 – Treatment options for antiplatelet therapy in the cathlab
8:10 – Interpreting the finding of ARCTIC study
15:14 – Bleeding risk in patients with complex disease
17:40 – Is there a role for platelet function testing in assessing compliance?
18:30 – Value of platelet function testing for assessing whether there is a drug response
22:30 – Is the P2′i’12 assay robust enough to titrate a response?
The panel for this session comprises:
Robert Storey, Professor and Honorary Consultant in Cardiology, Department of Cardiovascular Science, University of Sheffield, UK (Chair)
Jean-Philippe Collet, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Antonio Colombo, San Raffaele Hospital, Milan, Italy
Jeff Dahlen, Chief Scientific Officer at Accumetrics, US
Radcliffe Cardiology and Interventional Cardiology Review extends its thanks to all panel members.